Phaseline

Targets › LLT1

LLT1 (C-type lectin domain family 2 member D): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Receptor for KLRB1 that protects target cells against natural killer cell-mediated lysis. Inhibits osteoclast formation. (UniProt, Q9UHP7)

Open in Phaseline: the race on LLT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Zumutor BiologicsZM008
anti-LLT1 antibody
LLT1Phase 1Non Small Cell Lung CancerDec 2026

Conditions

Non Small Cell Lung Cancer (1)

Modalities

protein or peptide (1)

Companies

Zumutor Biologics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.